iCureCeliac

RSS feed for this section

iCureCeliac® Reports 16 Month Progress

iCureCeliac® is the only public celiac disease patient registry designed to help researchers better understand, and ultimately cure, celiac disease and non-celiac gluten/wheat sensitivity. iCureCeliac® allows patients to contribute medical information and their experiences living with celiac disease and non-celiac gluten/wheat sensitivity to advance life-changing initiatives in research, education, and advocacy. Your participation in iCureCeliac® will help […]

National Health Council Conference Focuses on Good Practices for Patient Engagement in Research

The pharmaceutical industry, the Food and Drug Administration, and disease advocacy organizations like Celiac Disease Foundation (CDF) are all seeking meaningful patient engagement in the drug research and development process. There is considerable evidence that when patients are active participants in disease research, the drug development process is not only more cost and time efficient, […]

Survey Results: Would You Use an In-Home Gluten-Detecting Test?

Celiac Disease Foundation recently administered a survey to gauge community interest in using a simple in-home urine or stool test to monitor gluten intake. Through our iCureCeliac® patient registry, we have found that 53% of people with celiac disease continue to experience symptoms while on a strict gluten-free diet. The most common reason for persistent […]

Partnership with ImmusanT to Promote Phase 2 Clinical Trial of Nexvax2®, A Promising Celiac Disease Treatment

ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial and is advancing to a Phase 2 trial. Currently, strict, lifetime adherence to a gluten-free diet is the only disease management protocol for celiac disease […]